Alexion Pharma (ALXN) Tops Q1 EPS by 15c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Alexion Reports First Quarter 2017 Results
April 27, 2017 6:30 AM EDT1Q17 Total Revenues of $870 Million, a 24% Increase and 26% Volume Increase Year-Over-Year Revenue Growth Benefited from Continued Strong Volume Growth of Soliris® In Core Markets Strensiq® Revenue Driven by Steady Addition of New Patients Starting Treatment Applications Filed in U.S., Europe and Japan for Soliris in Patients with Refractory gMG Enrollment in ALXN1210 Phase 3 Studies Advanced in Patients with PNH and aHUS New Phase 1 Data Support Advancing Development of ALXN1210 Subcutaneous Formulation Reiterating... More
